Home > Boards > US Listed > Miscellaneous >

MiMedx Group Inc. (MDXG)

Add MDXG Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 4/11/2022 9:21:45 AM - Followers: 31 - Board type: Free - Posts Today: 0

Management Team


MiMedx® has built a management team with highly experienced healthcare executives with track records of leading large healthcare organizations in generating growth, producing profitability, and increasing shareholder value. Our management team draws on guidance from an insightful board of directors and medical advisory board. Collectively, they are committed to achieving success, accomplishing our corporate goals and growing the company. The management team at MiMedx® includes:

Chief Executive Officer

Mr. Wright was appointed Chief Executive Officer effective May 13, 2019. Previously, Mr. Wright served as a Partner at Signal Hill Advisors, LLC, a consulting practice, since February 2011.

Interim Chief Financial Officer

Mr. Borkowski, was appointed Interim Chief Financial Officer on June 6, 2018. He previously served as Executive Vice President of MiMedx since April 19, 2018.

Chief Compliance Officer

Mr. Graves joined MiMedx in July 2018 and brings more than 20 years of pharmaceutical and biotech industry experience to the Company, ranging from compliance and sales management to government affairs.

General Counsel and Secretary

Mr. Hulse joined MiMedx in December 2019, and brings to MiMedx more than twenty years’ experience in large law firms and life sciences organizations, with significant legal, risk management, compliance and operational expertise.

Chief Medical Officer

Dr. Mason was named the Company’s Chief Medical Officer in December 2018. He joined MiMedx in June 2014, in the position of Vice President of Medical Affairs for Clinical Programs. Dr. Mason is a Board Certified Internist, board eligible in Rheumatology and Infectious Diseases, whose experience includes a 27-year pharmaceutical and medical device industry career, with increasing levels of responsibility.

Chief Scientific Officer

Dr. Koob is the Chief Scientific Officer of MiMedx. He is the senior executive responsible for the overall research direction and oversight of the Company’s product and tissue offerings.

Senior Vice President, Marketing and Business Development

Mr. Harris was named Senior Vice President, Marketing and Business Development in December 2018. He joined MiMedx as Senior Vice President, International in June 2018, bringing to the Company 20+ years of experience in the regenerative medicine, medical device and cell therapy fields. In this role, Mr. Harris is responsible for corporate and product marketing, partnerships and joint ventures, as well as international sales and operations.

Senior Vice President, Operations and Procurement

Scott Turner, has served as Senior Vice President, Operations and Procurement since April 2017. Mr. Turner oversees supply chain from donor recovery services through distribution as well as procurement, engineering, and facilities.

Vice President, Global Regulatory Affairs

Dr. Brown joined SpineMedica LLC, an early-stage predecessor company to MiMedx, in 2005. She initially served as the Director of Project Management and Senior Engineer for SpineMedica, and later served as its Director of Research and Development and as Vice President of Operations.

Vice President, Clinical and Scientific Liaison

Mr. Burrows joined MiMedx Group in April 2011 as Vice President of Wound Care to lead the marketing of the Company’s wound care offerings and other exciting products and tissues. He assumed the role Of Vice President of Global Marketing in August 2011 to focus on expanding the Company’s presence in the regenerative tissue market.

Vice President, Clinical Innovation

Mr. Spencer is the co-founder of Surgical Biologics, a leading processor of amnion tissue for use in a variety of surgical implants. Since the founding of Surgical Biologics in 2006, he led the development of the proprietary PURION® Process,



About MiMedx

MiMedx® is an industry leader in advanced wound care and an emerging therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied over 1.5 million allografts to date.


Contact and Stock Information


Hilary Dixon
Corporate & Investor Communications

Website: http://www.mimedx.com

Estimated Market Cap : $783.0M as of Dec 11, 2019

Outstanding Shares 110.8M as of December 11, 2018

$1.5M Settlement Recognizes Company's Cooperation & Remediation Efforts

MARIETTA, Ga., Nov. 26, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or the "Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it has finalized a settlement with the Securities and Exchange Commission (the "SEC"), resolving a previously disclosed investigation into the Company's financial accounting practices.

The Company has agreed to settle with the SEC, without admitting or denying the SEC's allegations, by consenting to the entry of a final judgment, subject to court approval, that permanently restrains and enjoins the Company from violating certain provisions of the federal securities laws. As part of the resolution, the Company also agreed to pay a civil penalty in the amount of $1.5 million. The settlement, if approved by the court, will conclude, as to the Company, the matters alleged by the SEC in its complaint.



Chair of the Board

Dr. M. Kathleen Behrens served as a member of the board of directors of each of Sarepta Therapeutics, Inc. (SRPT), a multi-billion dollar medical research and drug development company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, since March 2009

Chief Executive Officer

Mr. Wright was appointed Chief Executive Officer effective May 13, 2019. Previously, Mr. Wright served as a Partner at Signal Hill Advisors, LLC, a consulting practice, since February 2011.


Mr. Barry has served as a director of Elcelyx Therapeutics, Inc., a private pharmaceutical company, since February 2013 and has served as a Managing Member of GSM Fund, LLC, a fund established for the sole purpose of investing in Elcelyx Therapeutics, since February 2013.


Mr. Bierman served as President and Chief Executive Officer of Owens & Minor, Inc., a Fortune 500 company and a leading distributor of medical and surgical supplies, from September 2014 to June 2015.


Mr. Dewberry is a private investor with significant experience at both the management and board levels in the healthcare industry.


Mr. Evans has over 40 years of experience in the healthcare industry. He is currently President of the International Health Services Group, an organization he founded to support health services development in underserved areas of the world.


Mr. Koob joined the law firm of Simpson Thacher & Bartlett, LLP in 1970 and became a partner in 1977.


Mr. Newton has, since 2014, served as Chief Executive Officer and a member of the board of directors of Apollo Endosurgery, Inc. (APEN), a leader in the field of gastrointestinal therapeutic endoscopy.


Dr. Yeston is the Past President of the New England Surgical Society and currently serves as Active Senior Staff, Department of Surgery at Hartford Hospital.



Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MDXG News: Current Report Filing (8-k) 04:12 AM
MDXG News: Additional Proxy Soliciting Materials (definitive) (defa14a) 05/20/2022 12:11:30 PM
MDXG News: Leading Independent Proxy Advisory Firm Glass Lewis Recommends that MIMEDX Shareholders Vote “FOR ALL” of the Company’s Proposals 05/20/2022 05:00:00 AM
MDXG News: Additional Proxy Soliciting Materials (definitive) (defa14a) 05/18/2022 12:27:24 PM
MDXG News: MIMEDX Investor Presentation Highlights Clear Strategy for Value Creation 05/18/2022 12:18:33 PM
News News Alert: Current Report Filing (8-k) 05/24/2022 04:12:33 AM
#297   Marietta’s MiMedx moving past recent woes conix 04/11/22 09:21:45 AM
#296   MDXG Chart conix 09/13/21 11:24:46 AM
#295   looks like an opportunity to buy some MDXG dips... dealerschool2006 09/13/21 11:21:55 AM
#294   Massive buying opportunity!?!?!?! Termite7 09/13/21 10:16:14 AM
#293   ?? jkc2 09/07/21 04:32:03 PM
#292   Catching fire. Thanks for article, I'd think bleedpurple 04/06/21 06:10:54 PM
#291   01-Apr-21 09:35 ET Atlanta1 04/05/21 12:09:25 PM
#290   Something seems to be happening now... About bleedpurple 03/01/21 08:27:51 PM
#289   MDXG can't get no luv from the Market...I wiredawg 01/11/21 11:51:24 AM
#288   Had a decent move on 14 Dec 2020: wiredawg 12/24/20 02:26:33 PM
#287   * * $MDXG Video Chart 12-16-2020 * * ClayTrader 12/16/20 05:34:46 PM
#286   .... T695 11/09/20 04:19:54 PM
#285   MDXG moved to the Nasdaq from the OTC: Renee 11/04/20 09:03:48 AM
#284   https://mimedx.gcs-web.com/news-releases/news-release-details/mimedx-shares-comm Logon26 11/04/20 07:22:26 AM
#283   Today it’s over with OTC trading... Logon26 11/04/20 06:55:53 AM
#282   Spread 0.07 not so good for shorts to Logon26 11/03/20 01:22:05 PM
#281   shareholder letter we were approved for listing on Logon26 11/02/20 09:38:07 AM
#280   I don`t believe a word they say. Who TONYM 10/23/20 01:18:05 PM
#279   There’s a lot of short manipulation going on. Logon26 10/23/20 12:49:33 PM
#278   please show link or source--thank you TONYM 09/21/20 03:06:57 PM
#277   .... It will be uploaded to the Nasdaq Logon26 09/21/20 10:21:50 AM
#276   Yes Aug 11 monarch6500 08/05/20 12:34:56 PM
#275   again nice call--is cc conference call? TONYM 08/05/20 12:24:24 PM
#274   Upcoming CC may have an announcement on up-listing. monarch6500 08/05/20 12:47:17 AM
#273   I mean, you were off by 36 hours bleedpurple 06/17/20 10:38:25 PM
#272   What a good call--holding 13,000 shares TONYM 06/17/20 02:24:13 PM
#271   No particular reason except mdxg said they would monarch6500 05/30/20 08:38:26 PM
#270   your post 260, refers to June 15, 2020, TONYM 05/19/20 02:25:39 PM
#269   Soon, very soon monarch6500 05/19/20 01:48:06 PM
#268   Noles: VictorMasonIsRight 03/18/20 09:13:06 AM
#267   Pop w financials coming... back to 16 bleedpurple 02/20/20 11:27:02 PM
#266   Thanks for link, nice to hear and were bleedpurple 01/23/20 12:40:24 PM
#265   Another month or so for Finances and maybe nole92 01/19/20 02:58:10 PM
#264   OK. Here is a recent podcast from nole92 01/18/20 08:56:29 AM
#263   ...someone does know something...read my last msg and nole92 01/18/20 08:45:54 AM
#262   Restatement must be coming out soon. Rising price cars100cars 01/17/20 04:14:50 PM
#261   Recent downtrend is because a large option holder nole92 01/17/20 09:38:52 AM
#260   I'm thinking June 15, 2020 monarch6500 12/13/19 02:08:56 PM
#259   Updated financials early 2020. I've waited this bleedpurple 12/12/19 07:40:51 PM
#258   Hope everyone hangs in there next 3 days. nole92 12/11/19 10:26:07 PM
#257   From FIN Capital Management LLC: nole92 12/11/19 06:11:56 PM
#256   I'm guessing 2018 and 2019 revenue will be nole92 12/11/19 06:03:09 PM
#255   I hope they get the Super K out nole92 12/11/19 05:57:32 PM
#254   Current MiMedx AmnioFix Trials: nole92 12/11/19 05:55:36 PM
#253   I wonder if and when they will do nole92 12/11/19 05:52:52 PM
#252   Getting Close to Revised Financials release date. Mid cars100cars 12/10/19 12:56:00 PM
#251   I am liking the resolution. New management bleedpurple 11/30/19 07:12:09 PM
#250   Still not bankrupt. Sammy Beefkins 11/29/19 09:16:29 AM
#247   SEC Charges Biotech Company and Executives With Accounting Fraud Renee 11/26/19 04:27:37 PM
#246   Next report in December will be interesting, after Logon26 11/23/19 08:16:35 AM
Consent Preferences